FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Wockhardt's Free Cash Flow for the
three
months ended in Mar. 2026 was ₹0 Mil. Wockhardt's Revenue for the
three
months ended in Mar. 2026 was ₹9,650 Mil. Therefore, Wockhardt's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.
The historical rank and industry rank for Wockhardt's FCF Margin % or its related term are showing as below:
NSE:WOCKPHARMA'
s FCF Margin % Range Over the Past 10 Years
Min: -16.94 Med: -2.35 Max: 16.82
Current: 0.77
During the past 13 years, the highest FCF Margin % of Wockhardt was 16.82%. The lowest was -16.94%. And the median was -2.35%.
NSE:WOCKPHARMA's FCF Margin % is ranked worse than 55.09% of 962
companies
in the Drug Manufacturers industry
Industry Median: 2.51
vs NSE:WOCKPHARMA: 0.77
Wockhardt FCF Margin % Related Terms
Wockhardt FCF Margin % Historical Data
* Premium members only.
The historical data trend for Wockhardt's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:WOCKPHARMA vs ZTS, UTHR: FCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Wockhardt's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wockhardt FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wockhardt's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Wockhardt's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wockhardt (NSE:WOCKPHARMA) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Wockhardt and its competitors. According to the industry distribution chart, Wockhardt ranks #530 out of 962 companies in the Drug Manufacturers industry, placing it in the top 55.1%.
Is Wockhardt's FCF Margin % too high?
Wockhardt's current FCF Margin % is 0.00%. Based on the distribution chart, Wockhardt ranks #530 out of 962 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Wockhardt has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wockhardt's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Wockhardt ranks #530 out of 962 companies for FCF Margin %. This places Wockhardt in the lower half of its industry. The industry median FCF Margin % is 2.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Wockhardt and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wockhardt's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wockhardt stock overvalued right now?
Based on GuruFocus' analysis, Wockhardt (NSE:WOCKPHARMA) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,267.12, compared to a current price of ₹1,857.40 — trading 46.6% above its estimated fair value. The current FCF Margin % is 0.00%. Wockhardt's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Wockhardt (NSE:WOCKPHARMA), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wockhardt (NSE:WOCKPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Wockhardt stock appears to be overvalued.
The current stock price of ₹1,857.40 is trading 46.6% above its estimated GF Value™ of ₹1,267.12.
GuruFocus considers Wockhardt to be Significantly Overvalued.
Key valuation signals for NSE:WOCKPHARMA:
FCF Margin %: 0.00%
GF Value™: ₹1,267.12 vs. price of ₹1,857.40 (46.6% above fair value)
No single metric tells the full story. See the NSE:WOCKPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wockhardt Ltd is a drug manufacturing company focusing on pharmaceutical and biotechnology products. The group is involved in new drug discovery, contract manufacturing, API, vaccines, and branded pharmaceuticals business. In addition, it operates a chain of super-specialty hospitals. Its novel antibiotic platform has various assets, such as Zaynich (WCK 5222); Miqnaf (Nafithromycin), a macrolide-class respiratory antibiotic; Ertapenem-Zidebactam (WCK 6777); Foviscu (WCK 2482), an antibiotic for Gram-negative infections; and Odrate (WCK 6777), among others. The group is mainly engaged in the pharmaceutical business, which is considered its only reportable business segment. Geographically, it generates maximum revenue from Europe, followed by India, the USA, and the Rest of the world.
61GF Score
Get the complete analysis for NSE:WOCKPHARMA
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:WOCKPHARMA has been successfully added to your 
